Mie University · University Hospital · 講師

Research keywords腫瘍免疫・薬物療法・乳癌・CD204・プログラム死リガンド1・シスプラチン腎毒性・ゲノム解析

Research fields腫瘍診断、治療学

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• CD204-positive macrophages accumulate in breast cancer tumors with high levels of infiltrating lymphocytes and programmed death ligand-1 expression. 2021.01 Oncology letters 21 36-2021 · 主な業績等
• Risk factors for cisplatin-induced acute kidney injury: A pilot study on the usefulness of genetic variants for predicting nephrotoxicity in clinical practice. 2020.11 Molecular and clinical oncology 13 58-2020 · 主な業績等
• A randomized phase II study evaluating pyridoxine for the prevention of hand-foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer. 共著 2018.11 Breast cancer (Tokyo, Japan) 25 729-7352018 · 主な業績等
• [A Case of Poorly Differentiated Carcinoma of Unknown Primary Site with Risk of Choriocarcinoma Syndrome Effectively Treated with Reduced Bleomycin,Cisplatin ,Etoposide Combination Regimen(BEP Regimen)]. 共著 2018.04 Gan to kagaku ryoho. Cancer & chemotherapy 45 643-6452018 · 主な業績等

• トリプルネガティブ乳癌におけるがん幹細胞を標的とする新規CAR-T療法の開発
• IL-17による乳癌微小環境形成と転移促進作用の機序解明
• トラスツズマブ投与患者における細胞性免疫応答の誘導と抗腫瘍効果における役割の検討
• 治療抵抗性乳癌に対するGD2を標的とした新規免疫療法の開発

• Official profile